Working... Menu

Satisfaction and Compliance of Risedronate in PMO

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00549965
Recruitment Status : Completed
First Posted : October 26, 2007
Last Update Posted : October 30, 2007
Information provided by:

Brief Summary:
Compare subject satisfaction of once a week dosing of 35 mg Risedronate to once daily dosing of 5 mg Risedronate in postmenopausal osteoporotic women. Secondary objectives are to measure compliance (50 % drug taken), and persistence.

Condition or disease Intervention/treatment Phase
Osteoporosis, Postmenopausal Drug: Risedronate Sodium Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 202 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Prospective, Randomized, 2-Way Crossover, Open-Label Phase IV Study in Postmenopausal Women With Osteoporosis Examining Subject Satisfaction and Compliance When Actonel(Rosedronate) is Administered 35mg Once a Week or 5mg
Study Start Date : October 2003

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Primary Outcome Measures :
  1. Measurement of subject satisfaction of once a week 35 mg Risedronate and once daily 5 mg Risedronate. [ Time Frame: A subject-administered questionnaire at 12 and 24 weeks will assess satisfaction. ]

Secondary Outcome Measures :
  1. The subjects' compliance and persistence on treatment. Compliance as defined by more than 50% of the drug taken (by tablet count) during each Risedronate treatment period. [ Time Frame: Persistence at week 12 and 24 will be defined as continuing Risedronate treatment. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Five (5) years or greater postmenopausal who present with a diagnosis of postmenopausal osteoporosis based on standard clinical practice criteria.
  • Subjects must discontinue bisphosphonates, calcitonin, fluoride, glucocorticoids (> than or = to 5 mg prednisone or equivalent per day) and hormone replacement therapy including estrogen-related compounds at least 6 months prior to randomization. During the study, these drugs are not permitted other than the study medication, Risedronate.
  • Other concomitant medications should be kept to a minimum, but if the drugs are considered necessary for the subject's welfare and are unlikely to interfere with study medication they may be given at the discretion of the Investigator.

Exclusion Criteria:

  • Had a history of cancer within the past 5 years. Relatively benign skin malignancies, such as basal cell carcinoma or squamous cell carcinoma, are not an exclusion if the subject has been in remission for at least 6 months prior to enrollment.
  • Diagnosis of hypocalcemia, hyperparathyroidism, and hyperthyroidism.
  • History of alcohol and/or drug abuse.
  • Subjects will be excluded for active gastrointestinal disease that may interfere with absorption or with ability to swallow an oral medication.
  • Subjects will also be excluded for serious concurrent illness that would interfere with their ability to participate in the trial.
  • Excluded medications: bisphosphonates, calcitonin or fluoride or hormone replacement therapy within the last 6 months.
  • Known hypersensitivity to bisphosphonates and/or excipients.
  • Abnormal laboratory parameters, which are clinically relevant according to the Investigator (including renal insufficiency; creatinine clearance < 30 mL/min)

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00549965

Layout table for location information
Korea, Republic of
Daegu, Korea, Republic of
Sponsors and Collaborators
Layout table for investigator information
Study Director: Choe Seong Choon Sanofi

Layout table for additonal information Identifier: NCT00549965     History of Changes
Other Study ID Numbers: HMR4003B_4035
First Posted: October 26, 2007    Key Record Dates
Last Update Posted: October 30, 2007
Last Verified: October 2007

Additional relevant MeSH terms:
Layout table for MeSH terms
Osteoporosis, Postmenopausal
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Risedronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents